Biodata

 

Current Research interest:

• Viral gene therapy on type I diabetes using adeno-associated virus (AAV).
• Glucose responsive gene expression system in expressing human insulin.

 

Employment History:

June 2023 – Current   June 2014 – June 2023   May 2013 – March 2014   Dec 2004 – April 2013	Senior Research Fellow Phoenix Laboratory, Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore Research Fellow Phoenix Laboratory, Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore Research Fellow Laboratory of Cancer Gene Therapy, National Cancer Center Singapore Research Officer Laboratory of Cancer Gene Therapy, National Cancer Center Singapore
Aug 2003  – Nov 2004	Research Assistant Molecular Biology & Microbiology Laboratory, Department of Biology, Faculty of Science, Universiti Teknologi Malaysia
Apr 1999 – June 1999	Research Assistant Genetic Laboratory II, Department of Bioprocess Engineering, Faculty of Chemical & Natural Resources Engineering, Universiti Teknologi Malaysia

 

Academic qualifications and related awards:

2006  – 2013 Status: Completed	Doctor of Philosophy (Ph.D.) in Physiology Yong Loo Lin School of Medicine, National University of Singapore CAP: 4.67/5.00
2001 – 2004 Status: Completed	Master of Science (M.Sc.) in Biotechnology Faculty of Science, Universiti Teknologi Malaysia National Science Fellowship Award from Ministry of Science, Technology and the Environment of Malaysia’s government
1997 – 2001 Status: Completed	Bachelor of Science (Hons) in Industrial Biology (1st Class) Faculty of Science, Universiti Teknologi Malaysia First class honors with CGPA: 3.92/4.00 Academic excellence award in conjunction with 27th convocation Best student award of Faculty of Science Dean’s list for all semesters Best presenter award of symposium of undergraduate project

 

Publications List:

Sia KC, Gan SU, Mohd Rodhi SH, Fu ZY, Kopchick JJ, Waters MJ, Lee KO. First use of gene therapy to treat growth hormone resistant dwarfism in a mouse model. Gene Ther. 2022.(5-Year IF:4.9)
Sia KC, Fu ZY, Calne RY, Nathwani AC, Lee KO, Gan SU. Modification of a Constitutive to Glucose-Responsive Liver-Specific Promoter Resulted in Increased Efficacy of Adeno-Associated Virus Serotype 8-Insulin Gene Therapy of Diabetic Mice. Cells. 2020 (5-Year IF:6.7)
Recino A, Gan SU, Sia KC, Sawyer Y, Trendell J, Kay R, Gribble FM, Reimann F, Foale R, Notaridou M, Holmes N, Lever A, Lee KO, Nathwani A, Cooke A, Calne R, Wallberg M. Immunosuppression overcomes insulin- and vector-specific immune responses that limit efficacy of AAV2/8-mediated insulin gene therapy in NOD mice. Gene Ther. 2019.(5-Year IF:4.9)
Gan SU, Fu Z, Sia KC, Kon OL, Calne R, Lee KO. Development of a liver-specific Tet-off AAV8 vector for improved safety of insulin gene therapy for diabetes. J Gene Med. 2019 (5-Year IF:3.5)
Gan SU, Notaridou M, Fu ZY, Lee KO, Sia KC, Nathwani AC, et al. Correction of murine diabetic hyperglycaemia with a single systemic administration of an AAV2/8 vector containing a novel codon optimized human insulin gene. Curr Gene Ther. 2016. (5-Year IF: 2.95)
   Yulyana Y, Tovmasyan A, Ho IA, Sia KC, Newman JP, Ng WH, et al. Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP(5+), Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma Multiforme. Stem Cell Rev. 2016;12:140-55. (5-Year IF: 3.44)
    Yulyana Y, Ho IA, Sia KC, Newman JP, Toh XY, Endaya BB, et al. Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling. Mol Ther. 2015;23:746-56. (5-Year IF: 6.21)
    Chong DQ, Toh XY, Ho IA, Sia KC, Newman JP, Yulyana Y, et al. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. BMC Cancer. 2015;15:255. (5-Year IF: 3.77)
      Miao L, Fraefel C, Sia KC, Newman JP, Mohamed-Bashir SA, Ng WH, et al. The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy. Br J Cancer. 2014;110:94-106. (5-Year IF: 5.31)
     Ho IA, Yulyana Y, Sia KC, Newman JP, Guo CM, Hui KM, et al. Matrix metalloproteinase-1-mediated mesenchymal stem cell tumor tropism is dependent on crosstalk with stromal derived growth factor 1/C-X-C chemokine receptor 4 axis. FASEB J. 2014;28:4359-68. (5-Year IF: 5.64)
       Sia KC, Huynh H, Chung AY, Ooi LL, Lim KH, Hui KM, et al. Preclinical evaluation of transcriptional targeting strategy for human hepatocellular carcinoma in an orthotopic xenograft mouse model. Mol Cancer Ther. 2013;12:1651-64. (5-Year IF: 5.90)
      Sia KC, Huynh H, Chinnasamy N, Hui KM, Lam PY. Suicidal gene therapy in the effective control of primary human hepatocellular carcinoma as monitored by noninvasive bioimaging. Gene Ther. 2012;19:532-42. (5-Year IF: 3.11)
      Sia KC, Chong WK, Ho IA, Yulyana Y, Endaya B, Huynh H, et al. Hybrid herpes simplex virus/Epstein-Barr virus amplicon viral vectors confer enhanced transgene expression in primary human tumors and human bone marrow-derived mesenchymal stem cells. J Gene Med. 2010;12:848-58. (5-Year IF: 2.21)
     Ho IA, Miao L, Sia KC, Wang GY, Hui KM, Lam PY. Targeting human glioma cells using HSV-1 amplicon peptide display vector. Gene Ther. 2010;17:250-60. (5-Year IF: 3.11)
     Wang GY, Ho IA, Sia KC, Miao L, Hui KM, Lam PY. Engineering an improved cell cycle-regulatable herpes simplex virus type 1 amplicon vector with enhanced transgene expression in proliferating cells yet attenuated activities in resting cells. Hum Gene Ther. 2007;18:222-31. (5-Year IF: 3.41)
     Sia KC, Wang GY, Ho IA, Khor HY, Miao L, Hui KM, et al. Optimal purification method for Herpes-based viral vectors that confers minimal cytotoxicity for systemic route of vector administration. J Virol Methods. 2007;139:166-74. (5-Year IF: 1.77)
     Lam PY, Sia KC, Khong JH, De Geest B, Lim KS, Ho IA, et al. An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas. Mol Ther. 2007;15:1129-36. (5-Year IF: 6.21)